Fedratinib in 2025 and beyond: indications and future applications

Abstract: Dysregulated JAK/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomat...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Blood Advances
المؤلفون الرئيسيون:	Alexander Coltoff, John Mascarenhas
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-04-01
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2473952925001041

مواد مشابهة

Fedratinib-Induced Kidney Injury Confirmed by Biopsy
حسب: Sophie Le Grand, وآخرون
منشور في: (2025-08-01)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
حسب: C. Harrison, وآخرون
منشور في: (2022-06-01)

Fedratinib inhibits ovarian cancer progression by downregulating QPCT expression
حسب: Ying Dong, وآخرون
منشور في: (2025-10-01)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
حسب: Danny Jeyaraju, وآخرون
منشور في: (2023-08-01)

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
حسب: J. Mascarenhas, وآخرون
منشور في: (2022-06-01)

Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
حسب: Adrian Duek, وآخرون
منشور في: (2025-01-01)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
حسب: Francesca Palandri, وآخرون
منشور في: (2023-08-01)

JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells
حسب: Nihal AlMuraikhi, وآخرون
منشور في: (2021-01-01)

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
حسب: Dandan Wu, وآخرون
منشور في: (2020-06-01)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
حسب: F. Passamonti, وآخرون
منشور في: (2022-06-01)

Excipients to 2025 and Beyond
حسب: R. C. Moreton
منشور في: (2024-03-01)

Cyclosporine and fedratinib combination therapy via modulating Th17/Treg balance in Rat model of membranous glomerulonephritis
حسب: Ali Ghassabi, وآخرون
منشور في: (2024-12-01)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
حسب: J.-J. Kiladjian, وآخرون
منشور في: (2022-06-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
حسب: V. Gupta, وآخرون
منشور في: (2022-06-01)

Crystallography: 1970 – 2025 and Beyond
حسب: Carolyn P Brock
منشور في: (2025-10-01)

Excipients to the year 2025 - and beyond.
حسب: Chris Moreton
منشور في: (2019-06-01)

Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway
حسب: Hao Ruan, وآخرون
منشور في: (2021-07-01)

Global Trends in Education: Artificial Intelligence, Postplagiarism, and Future-focused Learning for 2025 and Beyond – 2024–2025 Werklund Distinguished Research Lecture
حسب: Sarah Elaine Eaton
منشور في: (2025-03-01)

Navigating the next lap: 2025 and beyond
حسب: Tiing Leong Ang
منشور في: (2025-01-01)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
حسب: G. Tremblay, وآخرون
منشور في: (2022-06-01)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
حسب: P. Abraham, وآخرون
منشور في: (2022-06-01)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
حسب: Graham McIlroy, وآخرون
منشور في: (2025-01-01)

Deep brain stimulation for movement disorders: 2025 and beyond
حسب: Alfonso Fasano, وآخرون
منشور في: (2025-01-01)

Non-communicable diseases – towards the 2025 global targets and beyond
حسب: Tashi Wangdi
منشور في: (2017-11-01)

EHRA 2025- A voyage into the future!
حسب: Bharatraj Banavalikar
منشور في: (2025-03-01)

Projection of macroeconomic indicators in SME sector by 2025
حسب: Stevanović Mirjana, وآخرون
منشور في: (2016-01-01)

Classification of Urinary Tract Infections in 2025: Moving Beyond Uncomplicated and Complicated
حسب: Gernot Bonkat, وآخرون
منشور في: (2025-05-01)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
حسب: Rosa Ayala, وآخرون
منشور في: (2023-08-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
حسب: Claire N. Harrison, وآخرون
منشور في: (2021-05-01)

Oodatav ajakirja tuleviku informatsioon (2025–2029) / Erwartete Zukunftsinformation der Zeitschrift (2025–2029) / Expected information for the future of journal (2025–2029)
حسب: Matti Raudjärv
منشور في: (2025-06-01)

Oodatav ajakirja tuleviku informatsioon (2025–2029) / Erwartete Zukunftsinformation der Zeitschrift (2025–2029) / Expected information for the future of journal (2025–2029)
حسب: Matti Raudjärv
منشور في: (2025-06-01)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
حسب: Ruben A. Mesa, وآخرون
منشور في: (2021-05-01)

2025: A Bright Year Ahead for Future Pharmacology
حسب: Fabrizio Schifano
منشور في: (2025-01-01)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
حسب: V. Gupta, وآخرون
منشور في: (2022-06-01)

The Australian maternal vaccination landscape in 2025 and beyond: New recommendations and strategies to improve uptake
حسب: Lisa McHugh, وآخرون
منشور في: (2025-10-01)

Editorial: Digital bridges and virtual scaffolds: reimagining open and distance learning for 2025 and beyond
حسب: Kam Cheong Li, وآخرون
منشور في: (2025-05-01)

Positive Energy Districts and deep renovation actions to move beyond the 2025 EU Targets
حسب: Rosa Romano, وآخرون
منشور في: (2022-07-01)

Indications for pediatric lung transplantation in 2025: A new era
حسب: Nicholas Avdimiretz, MD FRCPC, وآخرون
منشور في: (2025-08-01)

Investing in the future: addressing the rising cost of perfusion education in 2025
حسب: Johnson Blaine
منشور في: (2025-09-01)

Examining the Concepts of Future and Experimentation in Architecture through Expo2025
حسب: Ayşegül ÇELENK ÇAVDAR, وآخرون
منشور في: (2025-07-01)